Adjuvant Sorafenib for the Treatment of HCC (Phase III STORM Trial)
Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses results of the phase III STORM trial in hepatocellular carcinoma.
Clinical Pearls
Ghassan K. Abou-Alfa, MD, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, discusses results of the phase III STORM trial in hepatocellular carcinoma.
- The phase III STORM trial was a randomized, double-blind, placebo-controlled study of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma.
- Results showed no difference in recurrence-free survival (33.4 months with sorafenib vs 33.8 with placebo).
- It remains to be seen if targeting cancer cells in the adjuvant setting with an anti-angiogenic drug is correct or if another concept might be more appropriate.
Recent Videos
Related Content
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Article
Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
